The patients,were at various stages of treatment with an alpha-1 receptor blocker (Tamsulosin) and/or an alpha-reductase inhibitor (Finasteride) to reduce the size of the prostate, such that some had regained a more normal peak flow rate (w10mL:s{1) at the time of the trial.